<DOC>
	<DOCNO>NCT00705419</DOCNO>
	<brief_summary>Nonrandomized , prospective , observational , multi-site registry ass long-term safety , clinical outcome , death , evolution viral tropism HIV subject complete discontinued participation Phase 2 3 clinical trial involve vicriviroc . Subjects follow 5 year .</brief_summary>
	<brief_title>Registry Assess Long-term Outcome HIV Subjects Who Participated Phase 2 3 Clinical Trials Involving Vicriviroc ( Study P04999 )</brief_title>
	<detailed_description>A non-probability sampling method use . Subjects request enroll registry complete discontinued participation Phase 2 3 study involve vicriviroc .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Subjects must participate Phase 2 3 study involve vicriviroc , must receive , long receive study medication . Unwillingness participate registry give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>